Home/Filings/4/0000899243-23-020075
4//SEC Filing

Ege David S. 4

Accession 0000899243-23-020075

CIK 0001609809other

Filed

Oct 30, 8:00 PM ET

Accepted

Oct 31, 9:39 PM ET

Size

12.4 KB

Accession

0000899243-23-020075

Insider Transaction Report

Form 4
Period: 2023-10-27
Ege David S.
See Remarks
Transactions
  • Exercise/Conversion

    Common Stock

    2023-10-27+11,36171,057 total
  • Exercise/Conversion

    Restricted Stock Units

    2023-10-2711,36111,360 total
    Common Stock (11,361 underlying)
  • Sale

    Common Stock

    2023-10-30$1.35/sh4,066$5,48966,991 total
  • Award

    Restricted Stock Units

    2023-04-27+22,72122,721 total
    Common Stock (22,721 underlying)
Footnotes (4)
  • [F1]On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 17, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs.
  • [F3]The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.3425 to $1.405, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.

Issuer

Seres Therapeutics, Inc.

CIK 0001609809

Entity typeother

Related Parties

1
  • filerCIK 0001829360

Filing Metadata

Form type
4
Filed
Oct 30, 8:00 PM ET
Accepted
Oct 31, 9:39 PM ET
Size
12.4 KB